NASDAQ
Viking Therapeutics, Inc. (VKTX) closed at $36.15 in the latest trading session, marking a -2.51% move from the prior day....
Investment strategist Shay Boloor has outlined ten sub-$10 billion market-cap companies he believes are positioned to benefit from powerful long-term trends heading into 2026....
Together, these stocks offer you a balanced mix of growth and safety. These companies span a number of industries, and many are leaders in their markets....
Frontier Capital Management Co. LLC raised its stake in shares of Viking Therapeutics, Inc. (NASDAQ: VKTX) by 52.8% during the second quarter, according to the company in its most recent 13F filing wi...
The best-performing stock on this list is up just 4% this year. Investors may be undervaluing these companies' growth opportunities....
Viking Therapeutics is positioned for a pivotal 2026, advancing both injectable and oral VK2735 in obesity, with pipeline depth from an emerging amylin agonist program. VKTX's oral VK2735 has demonstr...
Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments....
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often ...
Viking Therapeutics could enter the weight loss market by 2029. The company's leading candidate looks very promising....
SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an...
No price data available for this timeframe.